Journal
ACTA NEUROPATHOLOGICA COMMUNICATIONS
Volume 9, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s40478-021-01151-4
Keywords
Glioblastoma; Mesenchymal transition; Master transcriptional regulator; Transcriptomic plasticity; TAMs
Categories
Funding
- Korea Healthcare Technology R&D Project - Ministry of Health & Welfare, Republic of Korea [HI11C21100200, HI18C0886]
- Industrial Strategic Technology Development Program - Ministry of Trade, Industry & Energy (MI, Korea) [10050154]
- Original Technology Research Program for Brain Science through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [2015M3C7A1028926, 2017M3C7A1044367]
- Original Technology Research Program for Brain Science through the NRF - Ministry of Education, Science and Technology [2017M3C7A1047392]
- Bio & Medical Technology Development Program of the National Research Foundation (NRF) - Ministry of Science ICT [2020M3A9G802202921]
- National Research Foundation of Korea [2017M3C7A1047392, 2017M3C7A1044367] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
GBM remains a challenging disease to treat due to its high intra- and inter-tumoral heterogeneity, with the mesenchymal subtype being associated with the most aggressive and treatment-resistant features. Research efforts have focused on identifying and understanding the master mesenchymal regulators and their downstream signaling pathways in order to develop more personalized therapeutic strategies.
Despite aggressive multimodal treatment, glioblastoma (GBM), a grade IV primary brain tumor, still portends a poor prognosis with a median overall survival of 12-16 months. The complexity of GBM treatment mainly lies in the inter- and intra-tumoral heterogeneity, which largely contributes to the treatment-refractory and recurrent nature of GBM. By paving the road towards the development of personalized medicine for GBM patients, the cancer genome atlas classification scheme of GBM into distinct transcriptional subtypes has been considered an invaluable approach to overcoming this heterogeneity. Among the identified transcriptional subtypes, the mesenchymal subtype has been found associated with more aggressive, invasive, angiogenic, hypoxic, necrotic, inflammatory, and multitherapy-resistant features than other transcriptional subtypes. Accordingly, mesenchymal GBM patients were found to exhibit worse prognosis than other subtypes when patients with high transcriptional heterogeneity were excluded. Furthermore, identification of the master mesenchymal regulators and their downstream signaling pathways has not only increased our understanding of the complex regulatory transcriptional networks of mesenchymal GBM, but also has generated a list of potent inhibitors for clinical trials. Importantly, the mesenchymal transition of GBM has been found to be tightly associated with treatment-induced phenotypic changes in recurrence. Together, these findings indicate that elucidating the governing and plastic transcriptomic natures of mesenchymal GBM is critical in order to develop novel and selective therapeutic strategies that can improve both patient care and clinical outcomes. Thus, the focus of our review will be on the recent advances in the understanding of the transcriptome of mesenchymal GBM and discuss microenvironmental, metabolic, and treatment-related factors as critical components through which the mesenchymal signature may be acquired. We also take into consideration the transcriptomic plasticity of GBM to discuss the future perspectives in employing selective therapeutic strategies against mesenchymal GBM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available